24 Jul 2026

CRC Research Update — July 24, 2026

Creator: The CRC Digest
Published: 2026-07-24T20:45:21Z

Today's colorectal cancer research highlights

3 min read

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

Signal Key

TRIAL DATA clinical trial results, efficacy data, survival endpoints TREATMENT new treatment options, regimen changes, combination therapies REGULATORY FDA/EMA approvals, guideline updates, NCCN/ESMO changes RESEARCH cancer biology, biomarker discoveries, resistance pathways SCREENING screening, colonoscopy guidelines, liquid biopsy, molecular profiling LIVING WITH CRC survivorship, quality of life, side effects, patient decision-making, caregiver support

CRC Research Update

RESEARCH
Non-Neutropenic Enterocolitis Risk Identified in Adjuvant CAPOX Therapy
A study examined the incidence and risk factors of non-neutropenic enterocolitis—a potentially serious side effect—in colorectal cancer patients receiving adjuvant capecitabine and oxaliplatin chemotherapy. (Clinical Colorectal Cancer)
TRIAL DATA
Copanlisib Plus Nivolumab Combination Fails to Meet Response Endpoint in MSS Colorectal Cancer
A phase 1/2 trial testing copanlisib (a PIK3CA inhibitor) combined with nivolumab in metastatic microsatellite stable CRC did not meet its primary endpoint, with 0 of 17 PIK3CA-wildtype patients and 2 of 22 PIK3CA-mutant patients achieving a 6-month treatment response. (Nature Communications)
RESEARCH
Mitochondrial Metabolism Drives 5-FU Resistance in Colorectal Cancer
Preclinical research shows that 5-fluorouracil treatment promotes mitochondrial biogenesis and increased mitochondrial function in surviving colorectal cancer cells, and that targeting mitochondrial metabolism—particularly Complex I inhibition—can sensitize CRC cells to chemotherapy. (Nature Metabolism)
TRIAL DATA
Phase Ib FIERCE Study Assesses Trifluridine/Tipiracil With Radiation in Rectal Cancer
A phase Ib study to assess the safety of neoadjuvant trifluridine/tipiracil combined with concurrent radiation in patients with resectable stage II/III rectal cancer. (Clinical Colorectal Cancer)

🔎 Screening Watch

Screening guidelines, early detection, and prevention advances

Systematic Review Examines CRC Screening Uptake in People Living With HIV
A systematic review and meta-analysis synthesized evidence on colorectal cancer screening uptake and lesion detection rates in people living with HIV, including comparisons with HIV-negative controls. (HIV Medicine)
Patient-Provider Relationship Quality Linked to Screening Uptake
A national study using HINTS data from 7,732 US adults aged 45-75 found that patient-provider relationship quality may influence colorectal cancer screening uptake. (Cureus)

💙 Living with CRC

Survivorship, quality of life, and supportive care

Latent Profile Analysis Identifies Distinct Quality of Life Patterns in CRC Survivors
Researchers used latent profile analysis of EORTC quality of life questionnaires to identify distinct health-related quality of life profiles among colorectal cancer patients, aiming to inform more personalized follow-up strategies. (Colorectal Disease)

🧬 Biomarker Spotlight

Research by genetic subtype — KRAS, BRAF, MSI-H, HER2, and more

Gut Microbiota Differs Between MSI-H and MSS Colorectal Cancer
A study collected fecal samples from CRC patients with different microsatellite states and healthy individuals to explore differences in gut microbiota between MSI-H and MSS colorectal cancer, potentially providing new directions for immunotherapy in MSS patients. (Frontiers in Cellular and Infection Microbiology)
CT-Based Imaging Biomarker May Predict MSI Status
A retrospective study of 121 CRC patients investigated whether CT-derived extracellular volume fraction can predict microsatellite instability status non-invasively. (American Journal of Translational Research)

⚥ Sex & Gender in CRC

Research on sex-specific differences in treatment, outcomes, and screening

Expert Consensus Calls for Sex and Gender-Tailored CRC Screening
An Italian consensus study from the AIOM-GISEG working group identified areas of expert agreement regarding the potential appropriateness and clinical relevance of sex and gender-tailored colorectal cancer screening strategies, noting that despite evidence of sex and gender disparities in CRC, no current clinical recommendations exist. (Frontiers in Oncology)

Research continues to advance our understanding of treatment resistance, screening strategies, and personalized care in colorectal cancer.

Get CRC research intelligence delivered weekly — free.

Browse by Topic

KRAS Mutations Immunotherapy (MSI-H)BRAF Early-Onset / Under 50 Liver Metastases Clinical Trials Living with CRC All Issues

CRC Research Update

Subscribe to The CRC Digest